期刊
CELL DEATH & DISEASE
卷 13, 期 2, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41419-022-04642-x
关键词
-
类别
资金
- National Natural Science Foundations of China [81872335]
- National Natural Science Youth Foundation [81902486]
- Natural Science Foundation of Henan [161100510300]
- Science and Technology Project of Henan Province [212102310187]
Esophageal squamous cell carcinoma (ESCC) is a highly prevalent malignant tumor, and current treatment strategies have limited efficacy. This study found that oxethazaine can inhibit ESCC proliferation and metastasis by targeting AURKA.
Esophageal squamous cell carcinoma (ESCC), a malignant neoplasm with high incidence, is a severe global public health threat. The current modalities used for treating ESCC include surgery, chemotherapy, and radiotherapy. Although ESCC management and treatment strategies have improved over the last decade, the overall 5-year survival rate remains <20%. Therefore, the identification of novel therapeutic strategies that can increase ESCC patient survival rates is urgently needed. Oxethazaine, an amino-amide anesthetic agent, is mainly prescribed in combination with antacids to relieve esophagitis, dyspepsia, and other gastric disorders. In the present study, we found that oxethazaine inhibited the proliferation and migration of esophageal cancer cells. According to the results of in vitro screening and binding assays, oxethazaine binds directly to AURKA, suppresses AURKA activity, and inhibits the downstream effectors of AURKA. Notably, we found that oxethazaine suppressed tumor growth in three patient-derived esophageal xenograft mouse models and tumor metastasis in vivo. Our findings suggest that oxethazaine can inhibit ESCC proliferation and metastasis in vitro and in vivo by targeting AURKA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据